Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

Table 3 Multivariate overall survival analyses including sidedness, the TP53 mutation status, and their interaction as covariates

	Coeff	e^Coeff (HR)	95%-CI	p	adjusted p
Stratified according to therapy (n = 141, number of events = 118)
Sidedness	0.57	1.77	1.06–2.95	0.030	0.090
TP53 mutation status	0.38	1.47	0.93–2.30	0.097	0.145
Sidedness: TP53 mutation status interaction	0.04	1.04	0.40–2.74	0.930	0.930
Anti-VEGF therapy (n = 72, number of events = 60)
Sidedness	0.34	1.40	0.71–2.76	0.326	0.489
TP53 mutation status	0.21	1.23	0.67–2.26	0.507	0.507
Sidedness: TP53 mutation status interaction	−1.20	0.30	0.04–2.52	0.268	0.489
Anti-EGFR therapy (n = 29, number of events = 26)
Sidedness	1.29	3.64	1.27–10.4	0.016	0.049
TP53 mutation status	1.00	2.71	1.02–7.17	0.045	0.068
Sidedness: TP53 mutation status interaction	−0.39	0.67	0.10–4.55	0.686	0.686

Multivariate survival analysis using Cox’s regression model - stratified according to therapy, for the group of anti-VEGF treated patients, and for the group of anti-EGFR treated patients

ISSN: 1471-2407